Validation, optimisation, and application data in support of the development of a targeted selected ion monitoring assay for degraded cardiac troponin T  by Streng, Alexander S. et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 7 (2016) 397–405http://d
2352-34
(http://c
DOI
n Corr
5800, 6
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleValidation, optimisation, and application data
in support of the development of a targeted
selected ion monitoring assay for degraded
cardiac troponin T
Alexander S. Streng a, Douwe de Boer a, Freek G. Bouwman b,
Edwin C.M. Mariman b, Arjen Scholten c,d,e,
Marja P. van Dieijen-Visser a, Will K.W.H. Wodzig a,n
a Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands
b Department of Human Biology, Maastricht University, Maastricht, the Netherlands
c Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht
Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
d Netherlands Proteomics Centre, Utrecht University, Utrecht, the Netherlands
e Current working address: Janssen, Pharmaceutical Companies of Johnson&Johnson, Infectious Diseases and
Vaccines, Leiden, the Netherlandsa r t i c l e i n f o
Article history:
Received 12 January 2016
Received in revised form
3 February 2016
Accepted 19 February 2016
Available online 3 March 2016x.doi.org/10.1016/j.dib.2016.02.051
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author at: Central Diagnostic L
202 AZ Maastricht, the Netherlands. Tel.: þ
ail address: will.wodzig@mumc.nl (W.K.W.a b s t r a c t
Cardiac troponin T (cTnT) fragmentation in human serum was
investigated using a newly developed targeted selected ion mon-
itoring assay, as described in the accompanying article: “Devel-
opment of a targeted selected ion monitoring assay for the eluci-
dation of protease induced structural changes in cardiac troponin
T” [1]. This article presents data describing aspects of the valida-
tion and optimisation of this assay. The data consists of several
ﬁgures, an excel ﬁle containing the results of a sequence identity
search, and a description of the raw mass spectrometry (MS) data
ﬁles, deposited in the ProteomeXchange repository with id PRIDE:
PXD003187.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.jprot.2015.12.028
aboratory, Maastricht University Medical Centre, P. Debyelaan 25. P.O. Box
31 043 3874977; fax: þ31 043 3874692.
H. Wodzig).
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Dubject area Clinical chemistry.
ore speciﬁc sub-
ject areaCardiovascular biomarkers.ype of data Figures, graphs, table, MS data.
ow data was
acquiredSDS-PAGE with Coomassie staining, MS data acquired with the Q Exactive
(Thermo Scientiﬁc), and an online database search.ata format Raw data (.raw, .msf, .xlsx) and analysed data (ﬁgures).
xperimental
factorscTnT fragments were created by spiking intact cTnT in human serum and
incubation at 37 °C for varying amounts of time.xperimental
featuresIntact and fragmented cTnT was puriﬁed by immunoprecipitation, separated by
SDS-PAGE, manually excised and digested with trypsin followed by relative
quantiﬁcation using targeted-SIM.ata source
locationMaastricht, the Netherlands.ata accessibility All ﬁgures are provided in this article. MS.raw- and.msf-ﬁles are deposited in the
ProteomeXchange repository with id PRIDE: PXD003187.Value of the data The mass spectrometry data identiﬁes multiple protein bands present in human serum as cardiac
troponin T.
 Our approach to relate the intensity of precursor ions of interest to a reference ion within the same
sample is a useful tool for gel-based targeted proteomics.
 Our approach to identify changes within a peptide can be used to accommodate other proteins and
modiﬁcations.
 Our data about tryptic cTnT precursor ions is invaluable to researchers studying the same protein.1. Data
The data in this article supports the validation and optimisation of a targeted selected ion
monitoring (t-SIM) assay used to analyse an observed fragmentation pattern of the protein cardiac
troponin T (cTnT) [1]. Fig. 1 depicts the amino acid sequence of cTnT with the targeted peptides of
interest highlighted in green, Fig. 2 shows the selected ion chromatogram and the MS/MS
identiﬁcation of these peptides, Fig. 3 shows the result of a collision energy optimisation
experiment performed on each single peptide, Fig. 4 shows precision plots of the validated assay,
and Fig. 5 depicts a Coomassie-stained image of a gel prior to the application of the ﬁnalised
method. All related mass spectrometry data is also publicly available via the ProteomeXchange
repository (PRIDE: PXD003187).2. Experimental design, materials and methods
2.1. Peptide speciﬁcity
The speciﬁcity of each targeted peptide for cTnT was veriﬁed by performing a sequence identity
search of all included peptides using the peptide match tool of the online Protein Information
Resource (PIR, http://research.bioinformatics.udel.edu/peptidematch/index.jsp) [2,3]. The database
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(84,539,639 sequences). Leucine and isoleucine residues were considered equivalent. The complete
search results are publicly available in the online data supplement (Sequence identity search.xlsx).2.2. Retention time approximation
The targeted cTnT peptides of interest (Fig. 1) were synthesised by Pepscan (Lelystad, the Neth-
erlands). The synthesised peptides were combined in equimolar amounts to create a synthetic pep-
tide standard.
This synthetic peptide standard was analysed with a data dependent (Top 10) method on a Q
Exactive hybrid quadrupole-Orbitrap mass spectrometer, connected to a UHPLC Proxeon Easy-nLC
1000 by Thermo Scientiﬁc (Waltham, MA, USA). Peptides were ﬁrst trapped on an Acclaim PepMap
100, 100 mm x 2 cm, C18, 5 mm, 100 A trap column in 0.1% TFA, 2% ACN and 98% water. Peptides were
subsequently separated on an Acclaim PepMap RSLC, 75 mm x 15 cm, C18, 2 mm, 100 A analytical
column by a 30 min gradient of 4–55% buffer B, followed by 55–90% B in 1 min and 90% B for 4 min at
a ﬂow rate of 300 nL/min.
Full scan MS spectra were acquired in the Orbitrap in the m/z range 250–1500 at a resolution of
70,000 full width at half maximum (FWHM) at 200 m/z, automatic gain control (AGC) of 1,000,000,
and a maximum injection time of 250 ms. The 10 most intense precursor ions were selected for
higher-energy collisional dissociation (HCD) with an isolation window of 1.2 Th and a normalised
collision energy (NCE) of 33%. Product ions were detected in the m/z range 250–1500 at a resolution
of 17,500 FWHM, AGC target of 100,000, maximum injection time of 200 ms, and a dynamic exclusion
window of 60 s.
Fig. 2a depicts the selected ion chromatogram of the synthetic peptide standard and shows the
retention times of all targeted peptides. MS/MS identiﬁcations of the targeted peptides are provided
in Fig. 2b. Obtained retention times from this data can be used to schedule targeted measurements on
the depicted cTnT precursor ions when using a similar chromatography setup and gradient. When
doing multiple experiments, shifts in retention time may be observed. It is therefore advisable to
acquire the current retention time of each target by measure the peptide standard prior to analysing
biological samples.Fig. 1. Annotated sequence of the canonical protein species of cardiac troponin T (cTnT). Green highlights indicate peptides of
interest that were synthesised and pooled in the synthetic peptide standard. The orange highlighted area is spliced in the
human adult cTnT protein species (isoform 6). The purple highlighted areas indicate the target epitopes of the clinical cTnT
assay by Roche Diagnostics. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
AEEDEEEEEAKEADGPMEESKPKPR, 4+ EAEDGPMEESKPKPR, 3+ 
EAEDGPmEESKPKPR, 3+ SFMPNLVPPK, 2+ 
SFmPNLVPPK, 2+ VDFDDIHR, 3+ 
DLNELQALIEAHFENR, 3+ KKEEEELVSLK, 3+ 
Fig. 2. a. Selected ion chromatogram of all targeted precursor ions as present in the synthetic standard. Inset shows the area
between 10.8 and 15.4 min containing several poorly ionisable precursor ions. b. Annotated MS/MS spectra identifying each of
the targeted precursor ions in the synthetic standard.
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ALSNMMHFGGYIQK, 3+ ALSNMmHFGGYIQK, 3+ 
ALSNmMHFGGYIQK, 3+ ALSNmmHFGGYIQK, 3+ 
VLAIDHLNEDQLR, 3+ AKELWQSIYNLEAEKFDLQEK, 4+ 
YEINVLR, 2+ INDNQKVSK, 2+ 
VRGRWK, 2+ AKVTGRW, 2+ 
Fig. 2. (continued)
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Fig. 3. Normalised collision energy (NCE) optimization of the selected precursor ions. MS2 spectra were recorded at nor-
malised collision energies varying between 26 and 32. The collision energy setting resulting in the highest signal (black) was
chosen for future experiments. AUC denotes area under the curve.
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Fig. 4. a. Precision plot depicting the instrument CV of the Q Exactive mass spectrometer versus the mean AUC of 16 selected
precursor ions of cTnT. Six technical replicates were injected into the mass spectrometer. b. Precision plot depicting the total CV
of the entire experimental workﬂow versus the mean AUC of 16 selected precursor ions of cTnT. Six technical replicates were
individually processed and injected into the mass spectrometer. Red data points indicate precursor ions with abnormally high
CV. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Normalised collision energies (NCE) were optimised using the synthetic peptide standard and a
targeted MS2 (PRM) method. The same chromatographic settings were used as described in Section 2.2.
Previously observed retention times and m/z values were used to target and isolate precursor ions of
interest (isolation window 1.2 Th) for HCD fragmentation at a resolution of 35,000, AGC of 100,000, and
a maximum injection time of 200 ms. NCE was varied between 26 and 32.
Integration of the product ion chromatograms was performed on the 6 most abundant fragment
ions using Skyline version 2.6 [4]. The total area under the curve (AUC) for each precursor ion then
equals the sum of the AUCs of the 6 most abundant fragment ions. The data in Fig. 3 depicts the total
AUC for each precursor ion at the different NCE settings. The NCE setting with the highest total AUC
for each precursor ion was used in future MS/MS measurements.
2.4. Analysis of technical replicates
Coefﬁcient of variation (CV) was calculated for the instrument by injecting the synthetic peptide
standard 6 times while using a t-SIM method. Additionally, the CV was calculated for 6 cTnT in-gel
digests prepared according to the workﬂow in [1]. The same chromatographic settings were used as
described in Section 2.2. SIM was performed on previously observed m/z values and retention times
at a resolution of 70,000 FWHM at m/z 200, AGC of 100,000, maximum injection time of 250 ms and a
detection window of 2.0 Th. The total AUC for each precursor ion equals the sum of the AUC of its M,
Mþ1 and Mþ2 isotopologues, as determined using Skyline version 2.6. From the data, precision plots
Fig. 5. Coomassie-stained gel image of incubated serum samples spiked with cTnT after immunoprecipitation. This gel was
used to excise protein bands for t-SIM analysis. cTnT bands at 37, 29, 19, 18, and 16 kDa are marked. Several common coeluting
proteins are also marked. IgG, immunoglobulin G; CK-M, creatine kinase M-type; M, molecular weight marker; P, positive
control; N, negative control.
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[1] (Fig. 4b.).
2.5. Sample preparation
The validated t-SIM assay is applied on serum samples spiked with puriﬁed human cTnT and
incubated at 37 °C. Prior to t-SIM analysis, cTnT is captured from serum using an immunoprecipitation
technique employing the M11.7 catcher antibody by Roche Diagnostics (Basel, Switzerland) based on
a protocol by Michielsen et al. [5]. This is followed by gel electrophoresis and Coomassie staining.
Fig. 5 depicts the Coomassie stained gel with several protein bands marked. In-gel digestion of the
bands marked 37, 29, 19, 18, and 16 kDa can be performed to obtain samples suitable for relative
quantiﬁcation using this t-SIM assay.
2.6. Direct link to deposited data
Mass spectrometry data (.raw-ﬁles and.msf-ﬁles) from the validation of this assay and data from
the application of the assay on samples obtained in Section 2.5 and [1] are deposited to the Pro-
teomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner
repository with the dataset identiﬁer PRIDE: PXD003187 [6,7].Acknowledgements
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assistance.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.02.051.
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